Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL3905 Target Snapshot

Tyrosine-protein kinase Lyn · SINGLE PROTEIN · Homo sapiens

3,003Compounds
804Assays
43Approved Drugs
2,209.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Tyrosine-protein kinase Lyn shows late clinical disease relevance led by chronic myelogenous leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P07948. Start with chronic myelogenous leukemia, then reuse UniProt P07948 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with chronic myelogenous leukemia, then reuse UniProt P07948 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug
Open source guide
Disease program
chronic myelogenous leukemia

Tyrosine-protein kinase Lyn shows late clinical disease relevance led by chronic myelogenous leukemia. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with chronic myelogenous leukemia because it currently carries late clinical support. Linked drugs include BOSUTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Late clinical Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Tyrosine-protein kinase Lyn as ChEMBL target CHEMBL3905, mapped to UniProt P07948. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Tyrosine-protein kinase Lyn
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3905
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P07948
Tyrosine-protein kinase Lyn
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Tyrosine-protein kinase Lyn is the right protein anchor across sources, using UniProt P07948 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why chronic myelogenous leukemia is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein kinase Lyn
UniProt AccessionP07948
Component TypeProtein
Sequence Length512 aa

Tyrosine-protein kinase Lyn

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Tyrosine-protein kinase Lyn, mapped to UniProt P07948. Sequence length is 512 aa.

Mapped IDP07948
Review nameTyrosine-protein kinase Lyn
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Tyrosine-protein kinase Lyn shows late clinical disease relevance led by chronic myelogenous leukemia. 5 more disease programs remain visible in the same review block.

Late clinical Phase III
chronic myelogenous leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugBOSUTINIB
Late clinical Phase III
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugBOSUTINIB
Clinical signal Phase II
Autosomal dominant polycystic kidney disease
1 linked drug · 1 direct · 1 efficacy
Linked drugBOSUTINIB
Clinical signal Phase II
breast cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugBOSUTINIB
Clinical signal Phase II
breast carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugBOSUTINIB
Clinical signal Phase II
chronic lymphocytic leukemia
1 linked drug · 1 direct · 1 efficacy
Linked drugBAFETINIB
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with chronic myelogenous leukemia because it currently carries late clinical support. Linked drugs include BOSUTINIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasechronic myelogenous leukemia
Strongest levelLate clinical
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

43
Approved
13
Phase III
36
Phase II
16
Phase I
Assay Mix

Activity Type Distribution

IC50768.0
KI649.0
EC50401.0
KD391.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL1171837 9.8 IC50 0.16 Approved
CHEMBL475584 9.4 IC50 0.4 Preclinical
CHEMBL388978 9.32 IC50 0.473 Preclinical
CHEMBL5416410 9.24 Kd 0.57 Approved
CHEMBL272888 9.05 IC50 0.9 Preclinical
CHEMBL249317 9.0 IC50 1.0 Preclinical
CHEMBL5416410 8.92 IC50 1.2 Approved
CHEMBL3647967 8.92 IC50 1.2 Preclinical
CHEMBL508928 8.9 Ki 1.259 Preclinical
CHEMBL1916879 8.81 IC50 1.55 Preclinical
Distribution

pChEMBL Value Distribution

61
5.0
111
5.5
221
6.0
129
6.5
95
7.0
65
7.5
51
8.0
29
8.5
10
9.0
2
9.5
pChEMBL
Approved Drugs

Approved Drugs

INFIGRATINIB
CHEMBL1852688
Approved 2021
INFIGRATINIB PHOSPHATE
CHEMBL1834657
Approved 2021
TIRBANIBULIN
CHEMBL571546
Approved 2020
FEDRATINIB
CHEMBL1287853
Approved 2019
ENTRECTINIB
CHEMBL1983268
Approved 2019
BRIGATINIB
CHEMBL3545311
Approved 2017
NERATINIB
CHEMBL180022
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
CERITINIB
CHEMBL2403108
Approved 2014
IBRUTINIB
CHEMBL1873475
Approved 2013
AFATINIB
CHEMBL1173655
Approved 2013
PONATINIB
CHEMBL1171837
Approved 2012
BOSUTINIB
CHEMBL288441
Approved 2012
VANDETANIB
CHEMBL24828
Approved 2011
CRIZOTINIB
CHEMBL601719
Approved 2011
PAZOPANIB
CHEMBL477772
Approved 2009
NILOTINIB
CHEMBL255863
Approved 2007
DASATINIB
CHEMBL5416410
Approved 2006
SUNITINIB
CHEMBL535
Approved 2006
DASATINIB ANHYDROUS
CHEMBL1421
Approved 2006
SORAFENIB
CHEMBL1336
Approved 2005
ERLOTINIB
CHEMBL553
Approved 2004
GEFITINIB
CHEMBL939
Approved 2003
IMATINIB
CHEMBL941
Approved 2001
Assay Landscape

Assay Landscape

804
Total Assays
499
Tested Compounds
3
Assay Types
Binding — 798 assays, 499 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 639 337 6.5
cell-based format 73 119 6.6
assay format 60 5 6.6
subcellular format 25 37 6.4
cell membrane format 1 1 8.5
ADME — 4 assays, 2 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 3 2 8.0
cell-based format 1 0
Functional — 2 assays, 202 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 201 6.9
cell-based format 1 1 6.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine